Immunovant Inc
IMVT26.050USD
-0.830-3.09%
Market hours （ET）Quotes delayed by 15 min
4.55BMarket Cap
LossP/E TTM
More Details of Immunovant Inc Company
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
Immunovant Inc Info
Ticker SymbolIMVT
Company nameImmunovant Inc
IPO dateMay 14, 2019
CEOVenker (Eric)
Number of employees362
Security typeOrdinary Share
Fiscal year-endMay 14
Address320 West 37Th Street
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10018
Phone19175803099
Websitehttps://immunovant.com/
Ticker SymbolIMVT
IPO dateMay 14, 2019
CEOVenker (Eric)
Company Executives of Immunovant Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
615.44K
-6.15%
Ms. Melanie Gloria
Ms. Melanie Gloria
Chief Operating Officer
Chief Operating Officer
173.51K
-6.78%
Mr. Douglas J. Hughes
Mr. Douglas J. Hughes
Independent Director
Independent Director
104.58K
-12.54%
Dr. Atul Pande, M.D.
Dr. Atul Pande, M.D.
Independent Director
Independent Director
95.41K
-14.51%
Dr. Jay S. Stout, Ph.D.
Dr. Jay S. Stout, Ph.D.
Chief Technology Officer
Chief Technology Officer
77.09K
-5.06%
Mr. Andrew J. (Drew) Fromkin
Mr. Andrew J. (Drew) Fromkin
Director
Director
69.66K
-24.21%
Mr. Jacob (Jake) Bauer
Mr. Jacob (Jake) Bauer
Independent Director
Independent Director
--
--
Mr. Robert G. Susman
Mr. Robert G. Susman
Independent Director
Independent Director
--
--
Mr. Tiago Girao
Mr. Tiago Girao
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
615.44K
-6.15%
Ms. Melanie Gloria
Ms. Melanie Gloria
Chief Operating Officer
Chief Operating Officer
173.51K
-6.78%
Mr. Douglas J. Hughes
Mr. Douglas J. Hughes
Independent Director
Independent Director
104.58K
-12.54%
Dr. Atul Pande, M.D.
Dr. Atul Pande, M.D.
Independent Director
Independent Director
95.41K
-14.51%
Dr. Jay S. Stout, Ph.D.
Dr. Jay S. Stout, Ph.D.
Chief Technology Officer
Chief Technology Officer
77.09K
-5.06%
Mr. Andrew J. (Drew) Fromkin
Mr. Andrew J. (Drew) Fromkin
Director
Director
69.66K
-24.21%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Nov 19
Updated: Wed, Nov 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Roivant Sciences Ltd.
55.91%
Fidelity Management & Research Company LLC
7.27%
Deep Track Capital LP
4.80%
The Vanguard Group, Inc.
3.36%
Armistice Capital LLC
2.88%
Other
25.78%
Shareholders
Shareholders
Proportion
Roivant Sciences Ltd.
55.91%
Fidelity Management & Research Company LLC
7.27%
Deep Track Capital LP
4.80%
The Vanguard Group, Inc.
3.36%
Armistice Capital LLC
2.88%
Other
25.78%
Shareholder Types
Shareholders
Proportion
Corporation
55.91%
Investment Advisor
21.12%
Hedge Fund
17.78%
Investment Advisor/Hedge Fund
5.51%
Research Firm
1.90%
Individual Investor
1.53%
Private Equity
0.78%
Sovereign Wealth Fund
0.34%
Pension Fund
0.30%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
487
96.71M
55.48%
-16.70M
2025Q2
493
194.27M
113.56%
-2.08M
2025Q1
505
194.81M
114.45%
+16.42M
2024Q4
482
163.29M
104.53%
-8.19M
2024Q3
464
162.18M
111.33%
-1.06M
2024Q2
453
157.67M
108.50%
+1.66M
2024Q1
433
151.47M
104.51%
-605.85K
2023Q4
420
150.13M
103.75%
+991.03K
2023Q3
373
143.75M
105.86%
+4.45M
2023Q2
335
132.11M
101.25%
-11.81M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Roivant Sciences Ltd.
96.65M
55.45%
--
--
Apr 21, 2025
Fidelity Management & Research Company LLC
18.33M
10.51%
+2.20M
+13.67%
Jun 30, 2025
Deep Track Capital LP
9.50M
5.45%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
7.01M
4.02%
+92.23K
+1.33%
Jun 30, 2025
Armistice Capital LLC
5.20M
2.98%
+700.00K
+15.56%
Jun 30, 2025
Baker Bros. Advisors LP
5.46M
3.13%
--
--
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
6.88M
3.95%
+984.13K
+16.69%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.11M
2.93%
+362.12K
+7.63%
Jun 30, 2025
Point72 Asset Management, L.P.
3.34M
1.91%
+2.53M
+316.03%
Jun 30, 2025
State Street Investment Management (US)
2.83M
1.62%
-257.02K
-8.33%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.05%
State Street SPDR S&P Biotech ETF
0.61%
ProShares Ultra Nasdaq Biotechnology
0.51%
Invesco Nasdaq Biotechnology ETF
0.42%
Direxion Daily S&P Biotech Bull 3X Shares
0.38%
iShares Biotechnology ETF
0.15%
Pacer WealthShield ETF
0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.1%
iShares Russell 2000 Growth ETF
0.1%
BNY Mellon US Small Cap Core Equity ETF
0.08%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.05%
State Street SPDR S&P Biotech ETF
Proportion0.61%
ProShares Ultra Nasdaq Biotechnology
Proportion0.51%
Invesco Nasdaq Biotechnology ETF
Proportion0.42%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.38%
iShares Biotechnology ETF
Proportion0.15%
Pacer WealthShield ETF
Proportion0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.1%
iShares Russell 2000 Growth ETF
Proportion0.1%
BNY Mellon US Small Cap Core Equity ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Immunovant Inc?
The top five shareholders of Immunovant Inc are:
Roivant Sciences Ltd. holds 96.65M shares, accounting for 55.45% of the total shares.
Fidelity Management & Research Company LLC holds 18.33M shares, accounting for 10.51% of the total shares.
Deep Track Capital LP holds 9.50M shares, accounting for 5.45% of the total shares.
The Vanguard Group, Inc. holds 7.01M shares, accounting for 4.02% of the total shares.
Armistice Capital LLC holds 5.20M shares, accounting for 2.98% of the total shares.
Roivant Sciences Ltd. holds 96.65M shares, accounting for 55.45% of the total shares.
Fidelity Management & Research Company LLC holds 18.33M shares, accounting for 10.51% of the total shares.
Deep Track Capital LP holds 9.50M shares, accounting for 5.45% of the total shares.
The Vanguard Group, Inc. holds 7.01M shares, accounting for 4.02% of the total shares.
Armistice Capital LLC holds 5.20M shares, accounting for 2.98% of the total shares.
What are the top three shareholder types of Immunovant Inc?
The top three shareholder types of Immunovant Inc are:
Roivant Sciences Ltd.
Fidelity Management & Research Company LLC
Deep Track Capital LP
Roivant Sciences Ltd.
Fidelity Management & Research Company LLC
Deep Track Capital LP
How many institutions hold shares of Immunovant Inc (IMVT)?
As of 2025Q3, 487 institutions hold shares of Immunovant Inc, with a combined market value of approximately 96.71M, accounting for 55.48% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -58.08%.
What is the biggest source of revenue for Immunovant Inc?
In --, the -- business generated the highest revenue for Immunovant Inc, amounting to -- and accounting for --% of total revenue.
